Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
International Biotechnology Trust (LSE:IBT) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
International Biotechnology Trust had a gross margin of 97.18% for the quarter that ended in Feb. 2026 => Durable competitive advantage
International Biotechnology Trust Gross Profit Related Terms
International Biotechnology Trust Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Biotechnology Trust Gross Profit Chart
LSE:IBT vs VRTX, REGN, MRNA: Gross Profit Comparison
For the Biotechnology subindustry, International Biotechnology Trust's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Biotechnology Trust Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Biotechnology Trust's Gross Profit distribution charts can be found below:
* The bar in red indicates where International Biotechnology Trust's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Feb. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was £76.43 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
International Biotechnology Trust (LSE:IBT) has a Gross Profit of £76.43 Mil as of Feb. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on International Biotechnology Trust and its competitors.
Is International Biotechnology Trust's Gross Profit too high?
International Biotechnology Trust's current Gross Profit is £76.43 Mil. Overall, International Biotechnology Trust has a GF Score™ of 43/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does International Biotechnology Trust's Gross Profit compare to VRTX and REGN?
International Biotechnology Trust's Gross Profit of £76.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on International Biotechnology Trust and its competitors. International Biotechnology Trust's current Gross Profit is £76.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Biotechnology Trust stock overvalued right now?
Based on GuruFocus' analysis, International Biotechnology Trust (LSE:IBT) is currently considered Significantly Undervalued. The stock's GF Value™ is £28.13, compared to a current price of £11.10 — trading 60.5% below its estimated fair value. The current Gross Profit is £76.43 Mil. International Biotechnology Trust's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For International Biotechnology Trust (LSE:IBT), the current Gross Profit is £76.43 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Biotechnology Trust (LSE:IBT) Overvalued in 2026?
Based on GuruFocus' analysis, International Biotechnology Trust stock appears to be undervalued.
The current stock price of £11.10 is trading 60.5% below its estimated GF Value™ of £28.13.
GuruFocus considers International Biotechnology Trust to be Significantly Undervalued.
Key valuation signals for LSE:IBT:
Gross Profit: £76.43 Mil
GF Value™: £28.13 vs. price of £11.10 (60.5% below fair value)
No single metric tells the full story. See the LSE:IBT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
43GF Score
Get the complete analysis for LSE:IBT
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IBT has been successfully added to your 
